Developments BlossomHill, Foundation Medicine to develop first CDx for BH-30643 in EGFR C797S-mutated NSCLC BlossomHill Therapeutics (NASDAQ: BLSM) has announced a collaboration with Foundation Medicine, a wholly owned subsidiary of Roche (SIX: RO, ROP; OTCQX: RHHBY), to develop the first companion diagnostic assay (CDx) for... October 22, 2026